CN118871113A - 使用THR-β激动剂的肝脏病症的治疗 - Google Patents

使用THR-β激动剂的肝脏病症的治疗 Download PDF

Info

Publication number
CN118871113A
CN118871113A CN202280087379.7A CN202280087379A CN118871113A CN 118871113 A CN118871113 A CN 118871113A CN 202280087379 A CN202280087379 A CN 202280087379A CN 118871113 A CN118871113 A CN 118871113A
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
liver
acceptable salt
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280087379.7A
Other languages
English (en)
Chinese (zh)
Inventor
C·T·琼斯
K·克拉奇
D·B·克里滕登
E·K·奎克
F·金
M·段
郭升
卞建卫
董倩倩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tuozhen Pharmaceutical Co
Original Assignee
Tuozhen Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tuozhen Pharmaceutical Co filed Critical Tuozhen Pharmaceutical Co
Publication of CN118871113A publication Critical patent/CN118871113A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
CN202280087379.7A 2021-11-11 2022-11-11 使用THR-β激动剂的肝脏病症的治疗 Pending CN118871113A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/130083 2021-11-11
CN2021130083 2021-11-11
CN2022097426 2022-06-07
CNPCT/CN2022/097426 2022-06-07
PCT/CN2022/131297 WO2023083288A1 (en) 2021-11-11 2022-11-11 TREATMENT OF LIVER DISORDERS WITH A THR-β AGONIST

Publications (1)

Publication Number Publication Date
CN118871113A true CN118871113A (zh) 2024-10-29

Family

ID=86335128

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280087379.7A Pending CN118871113A (zh) 2021-11-11 2022-11-11 使用THR-β激动剂的肝脏病症的治疗

Country Status (14)

Country Link
US (1) US20240293416A1 (https=)
EP (1) EP4429666A4 (https=)
JP (1) JP2024544538A (https=)
KR (1) KR20240101642A (https=)
CN (1) CN118871113A (https=)
AU (1) AU2022388507A1 (https=)
CA (1) CA3238108A1 (https=)
CL (1) CL2024001399A1 (https=)
CO (1) CO2024007225A2 (https=)
IL (1) IL312637A (https=)
MX (1) MX2024005647A (https=)
PE (1) PE20241327A1 (https=)
TW (1) TW202332447A (https=)
WO (1) WO2023083288A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
AU2020336272A1 (en) 2019-08-23 2022-04-14 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
WO2021050945A1 (en) 2019-09-12 2021-03-18 Terns, Inc. Thyroid hormone receptor beta agonist compounds
EP4568664B1 (en) 2023-04-07 2026-04-01 Terns Pharmaceuticals, Inc. Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity
WO2025245216A1 (en) * 2024-05-22 2025-11-27 Terns Pharmaceuticals, Inc. Treatment of liver disorders with a thr-beta agonist

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018075650A1 (en) * 2016-10-18 2018-04-26 Madrigal Pharmaceuticals, Inc. Methods of treating liver disorders or lipid disorders with a thr-beta agonist
AR115666A1 (es) * 2018-07-02 2021-02-10 Madrigal Pharmaceuticals Inc Formas sólidas de 2-(3,5-dicloro-4-((5-isopropil-6-oxo-1,6-dihidropiridazin-3-il)oxi)fenil)-3,5-dioxo-2,3,4,5-tetrahidro-1,2,4-triazin-6-carbonitrilo
CN111320609A (zh) * 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
WO2020228577A1 (zh) * 2019-05-10 2020-11-19 深圳微芯生物科技股份有限公司 一种哒嗪酮衍生物及其应用
TW202128668A (zh) * 2019-12-16 2021-08-01 大陸商江蘇恆瑞醫藥股份有限公司 并環類衍生物、其製備方法及其在醫藥上的應用
US20210379043A1 (en) * 2020-05-13 2021-12-09 Terns Pharmaceuticals, Inc. Combination treatment of liver disorders
CN114437034A (zh) * 2020-11-06 2022-05-06 深圳微芯生物科技股份有限公司 一种酞嗪类化合物的可药用盐、晶型及其制备方法

Also Published As

Publication number Publication date
TW202332447A (zh) 2023-08-16
WO2023083288A1 (en) 2023-05-19
KR20240101642A (ko) 2024-07-02
CL2024001399A1 (es) 2024-11-08
EP4429666A1 (en) 2024-09-18
CA3238108A1 (en) 2023-05-19
US20240293416A1 (en) 2024-09-05
CO2024007225A2 (es) 2024-10-31
AU2022388507A1 (en) 2024-06-20
EP4429666A4 (en) 2025-12-24
JP2024544538A (ja) 2024-12-03
IL312637A (en) 2024-07-01
PE20241327A1 (es) 2024-06-26
MX2024005647A (es) 2024-05-24

Similar Documents

Publication Publication Date Title
US20240293416A1 (en) TREATMENT OF LIVER DISORDERS WITH A THR-ß AGONIST
CN113518616B (zh) 用于治疗先天性肾上腺皮质增生症的crf1受体拮抗剂、其药物制剂和固体形式
JP6941109B2 (ja) Ｆｘｒアゴニストを使用するための方法
US20230241071A1 (en) Combination treatment of liver disorders
JP2024112818A (ja) 肝臓病
TW202207928A (zh) 肝病之組合治療
TW201932109A (zh) 治療肝臟疾病之方法
CN116096373A (zh) 用于治疗先天性肾上腺增生症的crf1受体拮抗剂
CN113908158A (zh) 使用fxr激动剂的方法
KR20230023642A (ko) 간 장애의 조합 치료
BRPI0719236A2 (pt) Composições de carbamato de fenilalquila
CN112755031A (zh) 用于治疗或预防心血管疾病的胆固醇酯转移蛋白抑制剂和含所述抑制剂的药物组合物
US20250120981A1 (en) Mrtx1133 pharmaceutical compositions
US12564600B2 (en) System for enhancing therapeutic compliance of the anti-cancer compound E7766
HK40118289A (zh) 使用THR-β激动剂的肝脏病症的治疗
TWI906348B (zh) 脂肪性肝疾病之治療劑
CN109789129B (zh) 自噬改良材料及其用途
JP7656359B2 (ja) アムホテリシンｂのハイブリッドアミド誘導体
HK40113179A (zh) 以回肠胆汁酸转运蛋白(ibat)抑制剂治疗以增加无事件存活期(efs)
HK40129994A (zh) 患有胆汁盐输出泵缺乏症的患者对asbti的基因型和剂量依赖性应答
TW202521110A (zh) 用於肝病之ｆａｓｎ抑制劑及ｇｌｐ－１促效劑之組合
BR112019009516B1 (pt) Usos de ácido 3?-araquidilamido-7?,12?-di-hidróxi-5?-colan24-oico (aramchol) ou sais farmaceuticamente aceitáveis dos mesmos

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40118289

Country of ref document: HK